45 completed, 13 active not recruiting, 10 recruiting, 10 terminated. 43 Phase 2, 17 Phase 3, 15 Phase 1, 5 Not applicable, 4 Phase 4.
Follow Janssen Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder Educational sessions - Schizophrenia Disorder, Schizoaffective Disorder | Not applicable | Not yet recruiting | Louisiana State University Health Sciences Center in New Orleans | 34 | 2026-03-01 | 2026-03-23 |
| Teclistamab-Daratumumab in AL Amyloidosis Teclistamab, Daratumumab and Hyaluronidase-fihj - Amyloid Light-chain Amyloidosis | Phase 2 | Recruiting | Rajshekhar Chakraborty, MD | 25 | 2025-11-07 | 2026-07-13 |
| Biomarkers of AKI in Patients Receiving Daratumumab Daratumumab - Acute Kidney Injury, Multiple Myeloma | Completed | Brigham and Women's Hospital | 20 | 2024-09-01 | 2026-02-27 | |
| Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma | Recruiting | Fox Chase Cancer Center | 92 | 2024-08-13 | 2025-10-31 | |
| Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism EHR (electronic health record) alert, No EHR (electronic health record) alert - Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis | Not applicable | Unknown | Scott C. Woller, MD | 152000 | 2024-06-01 | 2024-07-17 |
| Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody Daratumumab, Alemtuzumab, Sirolimus - Sickle Cell Disease | Phase 2 | Recruiting | Children's National Research Institute | 12 | 2024-04-03 | 2025-09-26 |
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Withdrawn | Alfred Chung, MD | 2024-01-08 | 2025-03-06 | |
| Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma Iberdomide, Daratumumab/rHuPH20 Co-formulation - Multiple Myeloma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 60 | 2023-12-21 | 2026-06-26 |
| A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) Cyclophosphamide, Bortezomib, Dexamethasone - Multiple Myeloma, Monoclonal Gammopathy of Renal Significance | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2023-10-16 | 2026-07-06 |
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy Talquetamab - Multiple Myeloma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-09-27 | 2026-03-04 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| TrEatment Approach in the Multimodal Era Registry Pulmonary endarterectomy, Balloon pulmonary angioplasty, Pulmonary hypertension (PH)-specific medication - Chronic Thromboembolic Pulmonary Hypertension, CTEPH | Active not recruiting | International CTEPH Association | 1000 | 2023-04-12 | 2026-10-26 | |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI Amivantamab, Lazertinib, Zirabev - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 60 | 2023-03-27 | 2026-01-21 |
| Improving HIV-1 Control in Africa With Long Acting Antiretrovirals Cabotegravir/Rilpivirine, Antiretroviral - HIV-1-infection | Phase 3 | Completed | MRC/UVRI and LSHTM Uganda Research Unit | 540 | 2022-12-08 | 2026-10-09 |
| Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA) - Human Immunodeficiency Virus Type 1 (HIV-1) | Phase 3 | Completed | ViiV Healthcare | 94 | 2022-11-08 | 2024-11-26 |
| Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects CD388 Injection, Saline placebo - Healthy | Phase 1 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 28 | 2022-10-18 | 2024-10-01 |
| The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Saline placebo, CD388 - Influenza | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 59 | 2022-09-09 | 2024-09-19 |
| Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults Ad26.Mos4.HIV, MVA-BN-HIV, PGT121 - HIV, Acquired Immunodeficiency Syndrome | Phase 1 / Phase 2 | Completed | Boris Juelg, MD PhD | 28 | 2022-04-01 | 2026-05-29 |
| Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects CD388 Injection, Saline placebo - Healthy | Phase 1 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 77 | 2022-03-14 | 2025-02-27 |
| Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp - SARS-CoV-2 Infection | Phase 1 / Phase 2 | Unknown | Mahidol University | 690 | 2021-12-20 | 2022-09-13 |
Showing 20 of 88. Sign in to see all of them.
HIV Infections (14) · Multiple Myeloma (13) · Acquired Immunodeficiency Syndrome (10) · Prostatic Neoplasms (6) · Immunoglobulin Light-chain Amyloidosis (4) · Infections (4) · Diabetes Mellitus (3) · Anemia, Sickle Cell (2) · Anxiety Disorders (2) · Leukemia, Myeloid, Acute (2) · Neoplasm Metastasis (2) · Psoriasis (2) · Psychotic Disorders (2) · Recurrence (2) · Schizophrenia (2)
daratumumab (19) · Dexamethasone (11) · Risperidone (5) · dolutegravir (5) · Bortezomib (4) · Calcium Dobesilate (4) · Lenalidomide (4) · Rilpivirine (4) · apalutamide (4) · cabotegravir (4) · Cyclophosphamide (3) · Prednisone (3) · carfilzomib (3) · etravirine (3) · Automobiles (2)
United States (64) · Germany (13) · Spain (13) · United Kingdom (13) · Canada (11) · France (11) · Belgium (10) · Italy (10) · Netherlands (8) · South Africa (7) · Argentina (6) · Russia (5) · Australia (4) · Brazil (4) · Ireland (4)
Ozlem Equils, MD (3) · Alfred Chung, MD (2) · Ajay K. Gopal (1) · Alexander Kutikov, M.D. (1) · Angela Bates, MD (1) · Anthony Ciesielski, MD (1) · Arun Anandakumar, MD (1) · Barbara Rothbaum, Ph.D. (1) · Beatriz Grinsztejn, MD, PhD (1) · Boris D Juelg, MD PHD (1) · Carl Landgren, MD (1) · Catherine Avitabile, MD (1) · Ciaffi Laura, Dr (1)
PMID 29239893, PMID 31307948, PMID 33136751, PMID 35508986, PMID 37452174, PMID 37776478, PMID 39052748, PMID 40655875, PMID 18681749, PMID 19042026, PMID 21871373, PMID 23782157, PMID 25381051, PMID 25385032, PMID 26059948, PMID 26263403, PMID 28566227, PMID 28625502, PMID 28750935, PMID 30428049, PMID 31122212, PMID 31201169, PMID 31315600, PMID 31371262, PMID 31528850, PMID 31533539, PMID 31873746, PMID 31978210, PMID 32049773, PMID 32130809, PMID 32773474, PMID 33259932, PMID 33794181, PMID 34148351, PMID 34228132, PMID 34557563, PMID 34655838, PMID 34656207, PMID 34978890, PMID 35142618, PMID 35986671, PMID 36039892, PMID 36413425, PMID 37227726, PMID 37340832, PMID 37344265, PMID 37509587, PMID 37914482, PMID 37945755, PMID 38717861
2014 (4), 2019 (3), 2016 (2), 2018 (2), 2017 (1), M01RR000069 (1), P30CA015704 (1), P50CA171963 (1), P50DA033945 (1), U01AI068636 (1), U01AI145801 (1), U01HL121518 (1)